National and Kapodistrian University of Athens
Ο ρόλος του βιολογικού δρόμου του πλακουντιακού αυξητικού παράγοντα σε ασθενείς με πλασματοκυτταρικές δυσκρασίες
Abstract
dc:descriptionMultiple myeloma (MM) is a neoplastic disorder characterized by the proliferation of a single clone plasma cell derived from B cells in the bone marrow. Frequently, the myeloma invades adjacent bone destroying skeletal structures and resulting in bone pain and fractures. Occasionally, plasma cells infiltrate multiple organs and produce other symptoms. The excessive production of a monoclonal (M) protein can lead to renal failure caused by Bence Jones proteinuria or hyper viscosity caused by excessive amounts of M protein in the blood. The diagnosis depends on the identification of abnormal monoclonal plasma cells in the bone marrow, M protein in the serum or urine, osteolytic lesions, and a clinical picture consistent with the diagnosis.Purpose of the study was to a) determine the levels of PlGF, sFlt1 and NGAL in patients with MM, b) investigate their possible use in the diagnosis and monitoring of the disease and eventually predicting the patients prognosis, c) investigate the correlation of these parameters with inflammation and/or bone marrow activity. The study included: i) 64 patients with newly diagnosed myeloma: 16 with asymptomatic (Smoldering) Multiple Myeloma (SMM) and 48 with symptomatic myeloma; ii) 8 with Monoclonal Gammopathy of Undetermined Significance (MGUS) and iii) 20 healthy controls.Compared to controls, patients with symptomatic MM had elevated circulating PlGF and elevated sFlt1 levels. Patients with MGUS and asymptomatic MM had no differences compared to controls for PlGF and sFlt1. In myeloma patients there was a strong correlation between circulating PlGF and sFlt1 levels. PlGF also correlated with IL-6 and CRP in MM patients. There was no difference for PlGF levels between patients with low and intermediate grade angiogenesis in asymptomatic myeloma. However, patients with asymptomatic myeloma and intermediate grade angiogenesis had elevated sFlt1 compared to patients with low grade angiogenesis. Similar results were obtained for patients with symptomatic myeloma.All patients with symptomatic myeloma received frontline therapy with novel agent-based regimens: 25 with lenalidomide-based regimens, 16 with thalidomide-based regimens and 7 with bortezomib-based regimens. The median follow-up period was 348 days and 8 patients have died. The probability of survival was 86% at 1 year and 78% at 2 years. In the univariate analysis the VEGFR-1 as a continuous variable correlated with higher risk of death. Furthermore it was found that: a) only patients with symptomatic MM had increased levels of Cys-C compared to controls, b) serum NGAL levels were elevated in all patients compared to controls, c) NGAL strongly correlated with both eGFR(Cys-C) and eGFR(MDRD), d) Cys-C showed strong correlation with eGFR and with the International Scoring System (ISS) (more pronounced in patients with ISS-3).In conclusion the study suggests that even though myeloma patients have increased circulating PlGF and sFlt1, sFlt1 plays a more important role since it correlates with increased angiogenesis and inferior survival, thus supporting a significant role of VEGFR-1 in the biology of angiogenesis in MM.Additionally, NGAL and Cys-C are very sensitive markers that reflect renal impairment in newly-diagnosed patients with multiple myeloma. The high levels of NGAL in asymptomatic patients and in MGUS patients support the hypothesis of the presence of renal damage in these patients early in the course of their disease and may reveal NGAL as an early marker that predicts the presence of RI in MM.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papassotiriou, Gerasimos Petros
- Παπασωτηρίου, Γεράσιμος-Πέτρος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39957